Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
Numinus to Acquire Novamind in Significant Psychedelic Therapy and Research Deal
04/12/2022
Numinus Wellness has entered into an agreement to acquire Novamind in a $26.2 million ($20.77 million US) deal announced by the 2 companies on Tuesday morning.
Numinus Wellness has entered into an agreement to acquire Novamind in a $26.2 million ($20.77 million US) deal announced by the 2 companies on Tuesday morning.
Numinus Wellness has entered...
04/12/2022
Behavioral Healthcare Executive

Advertisement

News
Lemborexant Improves Sleep, Reduces Daytime Fatigue in Patients With Insomnia
04/11/2022
A dual orexin receptor antagonist, lemborexant, improves sleep onset and sleep maintenance in patients with insomnia and reduces daytime fatigue, according to a recent study.
A dual orexin receptor antagonist, lemborexant, improves sleep onset and sleep maintenance in patients with insomnia and reduces daytime fatigue, according to a recent study.
A dual orexin receptor...
04/11/2022
Psych Congress Network
News
MDD Admissions Shift With Seasons, Study Finds
04/11/2022
A recent study in the Journal of Affective Disorders suggests seasonal fluctuations in inpatient admissions for MDD, with rates dipping in the summer and December and highest in post-holidays winter.
A recent study in the Journal of Affective Disorders suggests seasonal fluctuations in inpatient admissions for MDD, with rates dipping in the summer and December and highest in post-holidays winter.
A recent study in the Journal of...
04/11/2022
Psych Congress Network
News
Adult ADHD Linked With More Frequent and Severe Sleep Disturbances
04/11/2022
Adults diagnosed with ADHD experienced sleep disorders more often, with sleep disturbances more severe, than adults with other psychiatric disorders.
Adults diagnosed with ADHD experienced sleep disorders more often, with sleep disturbances more severe, than adults with other psychiatric disorders.
Adults diagnosed with ADHD...
04/11/2022
Psych Congress Network

Advertisement

News
Prolonged-Release Ketamine Formulation Shows Promise for TRD in Trial
04/07/2022
In a study by HMNC Health, in partnership with Develco Pharma, an oral formulation of ketamine for treatment-resistant depression was associated with a larger improvement in patients and similar dissociative side effects compared with a...
In a study by HMNC Health, in partnership with Develco Pharma, an oral formulation of ketamine for treatment-resistant depression was associated with a larger improvement in patients and similar dissociative side effects compared with a...
In a study by HMNC Health, in...
04/07/2022
Psych Congress Network
News
Dementia Cases Projected to Top 152 Million Globally by 2050, US Cases Could Double
04/06/2022
By 2050, the number of people with dementia is expected to increase from an estimated 57.4 worldwide in 2019 to 152.8 million, according to a study published in The Lancet Public Health.
By 2050, the number of people with dementia is expected to increase from an estimated 57.4 worldwide in 2019 to 152.8 million, according to a study published in The Lancet Public Health.
By 2050, the number of people...
04/06/2022
Neurology
News
FDA Approves Dissolving Sublingual Film for Agitation in Schizophrenia, Bipolar I or II
04/06/2022
The FDA has approved IGALMI™ (dexmedetomidine), a dissolving sublingual film, for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The FDA has approved IGALMI™ (dexmedetomidine), a dissolving sublingual film, for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
The FDA has approved IGALMI™...
04/06/2022
Psych Congress Network

Advertisement

News
Esketamine Shows Antidepressant Efficacy Regardless of Sleep Disturbance in Treatment-Resistant Depression
04/05/2022
Esketamine nasal spray initiated with an antidepressant outperformed placebo in easing TRD regardless of the presence of sleep disturbance and in improving sleep after 8 days of treatment.
Esketamine nasal spray initiated with an antidepressant outperformed placebo in easing TRD regardless of the presence of sleep disturbance and in improving sleep after 8 days of treatment.
Esketamine nasal spray initiated...
04/05/2022
Psych Congress Network
News
Mortality Risk Higher With ASD, ADHD
04/05/2022
ASD and ADHD are associated with a significantly increased risk of all-cause mortality, suggests a systematic review and meta-analysis published in JAMA Pediatrics.
ASD and ADHD are associated with a significantly increased risk of all-cause mortality, suggests a systematic review and meta-analysis published in JAMA Pediatrics.
ASD and ADHD are associated with...
04/05/2022
Psych Congress Network
News
Community-Level Social Support Infrastructure Linked with Reduced MDD Incidence
03/31/2022
New study reveals, adults from a high-risk neighborhoods experienced incident MDD at nearly half the rate when their communities offered social support programs.
New study reveals, adults from a high-risk neighborhoods experienced incident MDD at nearly half the rate when their communities offered social support programs.
New study reveals, adults from a...
03/31/2022
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use